Home
Apogenix

Apogenix Market Share Analysis for May 2026

apogenix develops innovative protein therapeutics for the treatment of cancer and other malignant diseases. our lead drug candidate apg101 has demonstrated a statistically significant efficacy in a controlled phase ii trial in recurrent glioblastoma.

Industry: N/A

Domainapogenix.com

Year Founded2005

Employees51 - 200

Annual Revenue$5M - $10M

Apogenix

Apogenix (including company regionals)

apogenix.com

See more website traffic and engagement information

Apogenix Revenue up to May 2026 is 5M - 10M

revenue generated by Apogenix top domains

Apogenix top domains revenue over 3 years

Revenue for Apogenix top domains

apogenix.com5M - 10M

See more with Sales Intelligence

Total visits to Apogenix's top domains

Understand Apogenix market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

apogenix.com1.6K

See more with Sales Intelligence

Avg. visit duration in Apogenix's top domains

Analyze Apogenix engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

apogenix.com00:00:34

See more with Sales Intelligence

Avg. pageviews on Apogenix's top domains

See how Apogenix keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

apogenix.com1.76

See more with Sales Intelligence

Apogenix top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Apogenix

These are the website technologies, by industry, used by Apogenix top domains

Email Services (2)

Microsoft Exchange Online

Payment & Currencies (2)

Visa

Audio Video Media (1)

YouTube

Content Management System (1)

Joomla

More Technologies

2

See all

News & Signals from Apogenix

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsApogenix receives financing of $27.2M in funding.German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.

NewsApogenix launches CD95 ligand inhibitor.Apogenix GmbH has added its CD95 ligand inhibitor, asunercept, to the band of cancer immunotherapies that are being repurposed to treat the most severe effects of COVID-19 infection.

NewsR-Biopharm AG partnered with Apogenix on Jul 29th '15.R-Biopharm AG, a global provider of innovative clinical diagnostics, announced today that it has entered into a research and development cooperation with Apogenix GmbH, a next generation immuno-oncology company, for the development of companion diagnostic tests (CDx) for Apogenix’ lead product APG101, a novel targeted anti-cancer therapy.